Concourse Financial Group Securities, Inc. Verve Therapeutics, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $0
- Q1 2025
Number of Shares
0
Previous 0
NaN%
Holding current value
$0
Previous $0
NaN%
% of portfolio
100.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding VERV
# of Institutions
203Shares Held
79.5MCall Options Held
204KPut Options Held
101K-
Alphabet Inc. Mountain View, CA12.3MShares$55 Million5.03% of portfolio
-
Bvf Inc San Francisco, CA6.9MShares$30.7 Million1.39% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$29.5 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY4MShares$17.8 Million2.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.96MShares$17.6 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $267M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...